A minority of injecting drug users, termed exposed uninfected, are resistant to hepatitis C (HCV) infection despite repeated low-dose exposures. We identify for the first time a cohort of blood recipients who remained uninfected despite large-dose exposure to HCV-contaminated blood and characterize immune factors that may confer protection. Of 1340 blood recipients from the English Look Back database who were transfused HCV-contaminated blood, we identified 8 who remained uninfected. In these 8 exposed uninfecteds, we characterized their natural killer (NK) cell populations and HCV-specific T-cell responses. Findings were compared with 10 spontaneous resolvers of HCV infection, 10 patients with chronic HCV infection and 10 healthy controls. Exposed uninfecteds had significantly greater numbers of NK cells with the activating receptor NKp30+ on CD56 bright and CD56 dim subsets compared with other groups (P < .05). Following interleukin-2 activation, NK cells of exposed uninfecteds had enhanced cytotoxicity that positively correlated with NKp30 expression (P = .02).
Summary
A minority of injecting drug users, termed exposed uninfected, are resistant to hepatitis C (HCV) infection despite repeated low-dose exposures. We identify for the first time a cohort of blood recipients who remained uninfected despite large-dose exposure to HCV-contaminated blood and characterize immune factors that may confer protection. Of 1340 blood recipients from the English Look Back database who were transfused HCV-contaminated blood, we identified 8 who remained uninfected. In these 8 exposed uninfecteds, we characterized their natural killer (NK) cell populations and HCV-specific T-cell responses. Findings were compared with 10 spontaneous resolvers of HCV infection, 10 patients with chronic HCV infection and 10 healthy controls. Exposed uninfecteds had significantly greater numbers of NK cells with the activating receptor NKp30+ on CD56 bright and CD56 dim subsets compared with other groups (P < .05). Following interleukin-2 activation, NK cells of exposed uninfecteds had enhanced cytotoxicity that positively correlated with NKp30 expression (P = .02).
Differences in NKp80 and KIR2DL3 expression were also observed. HCV-specific Tcell responses were observed in some exposed uninfecteds but of low amplitude.
Exposure without infection following transfusion of HCV-contaminated blood is a very rare phenomenon and suggests a high level of resistance to infection. Enhanced NK cell activation and killing, with weak HCV-specific T-cell responses, were observed many years after exposure in uninfected recipients and may contribute to protection from HCV acquisition, although additional protective factors are being sought in this important cohort.
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| INTRODUCTION
Hepatitis C virus (HCV) is an important cause of liver disease with a propensity to establish chronic infection. Only a minority of individuals are able to spontaneously clear the virus, which relies on the host mounting a successful immune response. [1] [2] [3] Not all individuals exposed to HCV, however, develop infection. We and others have previously reported on a novel phenotype of injecting drug users (IDUs) who have no evidence of infection, such as viraemia or anti-HCV antibodies (Ab), despite repeated HCV exposure through high-risk practices. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] We have termed these individuals as exposed uninfected (EU).
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Thus far, studies on EUs have focused on IDUs exposed to low doses of the virus. The phenomenon of exposure without infection has not been previously described in individuals parenterally exposed to large doses of HCV, such as following transfusion of contaminated blood products. In this study, we have identified and characterized a 
| MATERIALS AND METHODS

| Study population
The study population consisted of blood recipients identified from the NHS Look Back programme as being exposed to HCV via blood transfusion pre-1991, which was prior to universal HCV donor screening in the UK.
The Look Back programme was established in 1995 to trace and test recipients of blood products previously donated by blood donors who were subsequently found to be HCV-positive when screening was introduced. We have reviewed the Look Back cohort to identify those who did not develop any evidence of HCV infection despite confirmed high-dose exposure to HCV-contaminated blood products. We compared findings in these exposed uninfected cases with others who developed chronic infection or spontaneously resolved infection.
| EU cohort
From a total of 1340 blood recipients identified in the Look Back programme, eight EU cases were stringently selected. The following criteria were used:
1. Definitive history of exposure to HCV from blood products;
2. Both HCV Ab and HCV ribonucleic acid (RNA) undetectable;
3. All EU cases received blood from HCV-infected donors whose blood donations had transmitted HCV to at least one recipient before and one recipient after donating blood to that EU individual, providing confirmation that the donor was infectious at the time of donation; or, the EU individual had to have received part of a blood donation that was responsible for infecting another recipient, thus confirming the donation itself was contaminated.
| SR cohort
The SR cohort consisted of 10 blood recipients recruited from the Look Back programme who spontaneously cleared HCV following infection via blood transfusion, defined as anti-HCV Ab-positive and HCV RNA-negative.
| Chronic infection cohort
A cohort of 10 treatment naïve patients with blood transfusionacquired genotype 1 chronic HCV infection (anti-HCV Ab-and HCV RNA-positive for at least six months) were recruited from the South West Liver Unit clinic at Derriford Hospital, Plymouth.
| Healthy control cohort
A cohort of 10 healthy controls with no risk factors for HCV was also recruited from Derriford Hospital and University of Plymouth.
| Timing of HCV testing
All EU and SR blood recipients recruited from the Look Back pro- At study entry, each blood recipient was re-tested for anti-HCV Ab using a fourth-generation EIA assay, Monolisa HCV Ag-Ab Ultra (BioRad Laboratories, Hertfordshire, UK), and for HCV RNA by PCR using the Cobas Ampliprep/Cobas Taqman HCV Test v2.0 (Roche, California, United States; lower limit of detection 15 IU mL-1). 
| Ethics
| Peripheral blood mononuclear cells (PBMCs) isolation
PBMCs were isolated from whole blood using Ficoll (Sigma-Aldrich, Dorset, UK) density gradient centrifugation and cryopreserved for subsequent analyses.
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| Flow cytometry
Flow cytometry was performed using a four-channel BD Accuri C6 instrument (New Jersey, USA). was added prior to flow cytometry.
| Cytotoxicity assay
| IFN-γ production
Thawed PBMCs were stimulated with phorbol 12-myristate Unstimulated PBMCs served as the negative control.
| IFN-γ enzyme-linked immunospot (ELISpot) assay
ELISpot assays were performed as previously described. 
| Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics v20.
Results were expressed as medians unless stated otherwise.
Categorical data were compared using Fisher's exact test. Continuous data between two cohorts were compared using Mann-Whitney U test. With more than two cohorts, continuous data were compared using Kruskal-Wallis test. A statistically significant Kruskal-Wallis test was followed by post hoc analysis using Dunn's test for multiple comparisons between cohorts. Adjusted P values were calculated to correct for multiple comparisons. Pearson product-moment correlation coefficient (r) was calculated for correlation analysis. A line of best fit was drawn using linear regression. Statistical significance levels were determined by two-tailed tests (P < .05).
| RESULTS
Of the 1340 blood recipients identified as having received a contaminated blood product, 13 (1.0%) met the inclusion criteria for EU.
Eleven were alive, of which eight were recruited into the study.
Baseline demographics and transfusion details of the eight EUs are shown in Table 1 . Median age at time of transfusion was 21 years (IQR 13-32). There was no history of post-transfusion hepatitis. One participant, EU5, had biopsy-proven nonalcoholic fatty liver disease; the remaining seven had no history of liver disease or abnormal liver enzymes. There was a range of active medical conditions. No participant was on steroids or immunosuppression at the time of transfusion or recruitment. Table 2 shows the donor-recipient records for each of the donors that donated blood to our EUs. In five cases, the donors (X1, X2, X3, X5, X7) infected other recipients both before and after donating blood to our EUs (EU1, EU2, EU3, EU5, EU7, respectively), confirming the donors were infectious during this time. In the remaining three cases, donors X4, X6 and X8 each made a donation that was separated into components and transfused to more than one recipient (X4 to EU4 and R9; X6 to EU6 and R13; X8 to EU8 and R19). The other recipients developed infection, thereby confirming the donation itself, which the three EUs had also received, was contaminated. In all cases, the genotypes of the infected recipients matched those of their respective donors.
A further 10 participants were recruited into each of the remaining three cohorts. There were no significant differences in the baseline characteristics between the four cohorts. Median ages at study entry with chronic infection ( Figure 1) ; however, there was no difference in the distribution of NK cell subsets between EUs and the other cohorts (Figure 1 ), suggesting that the higher relative frequencies of NK cells in EUs were due to an increase in both CD56 bright and CD56 dim cells.
The numbers of NKp30+ NK cells were significantly higher in
EUs than in the other cohorts -vs SRs (P = .002), vs healthy controls (P = .01), and vs patients with chronic infection (P = .04) (Figure 2 ).
This increased expression of NKp30 in EUs was observed across both subsets. EUs had significantly greater numbers of CD56 dim NKp30+ cells when compared to SRs (P = .007) and healthy controls (P = .03), and trending towards significance when compared with the chronic infection cohort (P = .06) (Figure 2 ). In the CD56 bright subset, numbers of NKp30+ cells were highest in the EUs, significant against SRs (P = .047), healthy controls (P < .001) and those with chronic infection (P = .02) (Figure 2 ).
Other differences in receptor expression were also observed.
There were significantly higher levels of NKp80+ NK cells in EUs and
SRs than in healthy controls, although not so when compared with the chronic infection cohort (Figure 3 ). The expression of the inhibitory NK cell receptors was also examined. The only significant difference was observed with the killer cell immunoglobulin-like receptor, KIR2DL3, which was preferentially expressed on CD56 bright NK cells of both EUs and SRs (Figure 3 ).
| NKp30-high NK cells demonstrated enhanced
IL2-induced cytotoxicity
Cytotoxic activity of isolated NK cells (>90% purity) was determined to confirm whether differences in receptor expression were associated with enhanced killing potential. NK cells at rest had little cytotoxic activity and no differences were detected between cohorts. 
| T-cell-mediated IFN-γ responses to HCV
T-cell responses to genotypes 1b and 3a were assessed via ELISpot 
| DISCUSSION
This study describes a novel cohort of blood recipients with no clinical or serological evidence of infection despite verified exposure to HCV-contaminated blood. This is the first report of exposure without infection in the setting of large-volume intravenous inoculation Received blood product from the same donation. EU, exposed uninfected; HCV, hepatitis C. In table 2, the 8 participants that were recruited into this study (as exposed uninfected) have been cited in bold to highlight them as the blood recipients of interest in the study.
T A B L E 2 Donors of the eight EU participants and their corresponding recipients of HCV with 8 cases identified and traced after meticulous interrogation of the records from a well-conducted national look-back exercise dating back to the 1990s. Prior to this, exposure to HCV that did not result in infection had only been reported following much smaller inocula through IDU, 4-16 sexual contact [21] [22] [23] or needle stick injury.
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Transfusion-related HCV is, by and large, historical and so this cohort has considerable potential to advance our understanding of how highlevel resistance to HCV infection can be conferred.
We have shown that EU blood recipients have distinct differences NK cells was significantly higher in EUs than in healthy controls (P = .03) and SRs (P = .007). C, Similarly, in the CD56 bright subset, NKp30 levels were significantly increased in EUs when compared with healthy controls (P < .001), SRs (P = .047) and those with chronic infection (P = .02). NK, natural killer; CON, healthy control; EU, exposed uninfected; SR, spontaneous resolver; CHR, chronic infection et al 8 reported that increased NK cell cytotoxicity protected IDUs exposed to HCV from becoming infected and this enhanced cytotoxicity was associated with higher expression of NKp30. This study, therefore, supports NKp30-mediated NK cell cytotoxicity as a potential mechanism by which individuals exposed to HCV are protected from infection and appears to be relevant in both low-and high-dose exposures.
Other less striking differences were observed. NKp80 has an activating function, possibly by acting as coreceptor with other activating receptors. 25 EUs and SRs had significantly higher frequencies of NKp80+ NK cells than healthy controls, although levels were not statistically different when compared with those chronically infected.
The significance of increased NKp80 levels is unclear; NKp80 has not previously been implicated in the immune defence against HCV. In this study, half of EU blood recipients demonstrated IFN-γ-producing T-cell responses to HCV, similar to rates reported in both our 5 and other 7, [10] [11] [12] 24 IDU EU cohorts, where up to 60% have demonstrable T-cell responses. The T-cell responses in our EUs were directed at multiple HCV antigens, favouring a true HCV-specific response rather than cross-reactivity, which tends to target only NS3 and NS5B
due to homologous sequences shared with common viruses. 27, 28 The F I G U R E 3 Expression of NKp80 activating receptor and KIR2DL3 inhibitory receptor on NK cells in peripheral blood. A, Relative to healthy controls, NKp80 expression on NK cells was significantly higher in EUs (P = .009) and SRs (P = .045). NKp80 expression in those with chronic infection, however, was not significantly different from that seen in healthy controls. B, KIR2DL3 expression on CD56 bright NK cells was significantly higher in EUs than in healthy controls (P = .001) and those with chronic infection (P = .04). Increased expression was also noted in SRs relative to healthy controls (P = .006). NK, natural killer; CON, healthy control; EU, exposed uninfected; SR, spontaneous resolver; CHR, chronic infection F I G U R E 4 IL2-induced cytotoxicity of natural killer (NK) cells against K562 target cells and correlation with NKp30 expression. A, When NK cells were stimulated with IL2, cytotoxicity was significantly increased in the EUs relative to healthy controls (P = .01) and those with chronic infection (P = .04). B, IL2-induced cytotoxic activity of NK cells was positively correlated (r = .38) with the expression of NKp30 at a statistically significant level (P = .02). The line of best fit obtained with linear regression is also shown. IL2, interleukin-2; CON, healthy control; EU, exposed uninfected; SR, spontaneous resolver; CHR, chronic infection positive responses were, however, fairly weak in magnitude and so the extent to which T cells in EUs confer protection from HCV infection is controversial. A nested case-control series from a prospectively studied cohort of IDUs in Australia revealed no differences in T-cell responses between those who developed incident HCV infection and those who remained uninfected, suggesting that whilst HCV-specific cellular immunity is prevalent in EUs, it does not correlate with protection. 7 Thus, whilst the presence of low-level HCV-specific T-cell responses in half of our EU blood recipients provides further confirmation of HCV exposure, any role they have in protection remains unclear.
There are some limitations to this study. We defined EUs as being HCV antibody and HCV RNA-negative. However, as the first testing for HCV antibodies took place some years after exposure, it is possible that they were infected but lost HCV antibodies over time. This has been reported in SRs, but typically 18-20 years after a low-dose inoculation from anti-D immunoglobulin, 29 whereas EUs identified in this cohort were all tested within 10 years from exposure. The sample size was limited by the small number of uninfected individuals that met the very strict definition of HCV exposure. EU blood recipients represent an extremely rare cohort and, therefore, any study examining this unique group will be limited by small numbers and the difficulties that this poses. Furthermore, our results, like other studies on EU cohorts, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] were based on experiments using peripheral blood samples to obtain NK and T cells, when we know that the immune response to the virus is reliant on intrahepatic immune cells. However, to study intrahepatic immune cells would require invasive sampling of the liver, which is difficult to justify in EUs who are otherwise healthy.
In summary, we have defined a novel cohort with a uniquely high level of resistance to HCV infection. This small group of cases, identified and traced from a painstaking review of a much larger cohort of HCV-exposed blood recipients, remained uninfected despite a clear history of high-dose parenteral exposure to HCV-contaminated blood. These EU blood recipients, similar to IDU EU cases, demonstrate distinct differences in their innate immunity, with an activated NK cell phenotype and enhanced cytotoxicity, together with low-level adaptive HCV-specific T-cell responses in half of these cases identified many years after the HCV exposure. It remains unclear whether these differences alone are sufficient to explain the high-level resistance demonstrated by these unusual cases and further study of this important group of cases to identify other potential mechanisms of protection from HCV infection are ongoing.
